It is a dermatology brand's over-the-counter prostaglandin brow serum, built on dehydrolatanoprost with biotin, phenethyl caffeate, hyaluronate and panthenol around it and a twelve-week blinded study behind it, and it fills brows in the way only that class of ingredient does. Its distinction from conditioning brow serums is that it works; from the prescription, that it needs none; and from plain labelling, that the active is listed fourth and called a lipid.
A brow serum that fills in sparse and over-tweezed brows in two to three months because its fourth ingredient is a prostaglandin analogue, sold under a biotin-led vitamin name that puts the active behind the decoration. The class has randomised prescription evidence for brows and the product has a brand-held study; the fill is real, the skin darkening and irritation for a minority are real, the results leave when the serum does, and one hundred and fifty dollars for five millilitres is the dearest way to buy the molecule.
Obagi's efficacy figures for this serum come from a 2022 twelve-week blinded study held by the brand without a published subject count or peer review, and the concentration of dehydrolatanoprost is undisclosed. The assessment draws on nearly two hundred consumer reviews since launch, the disclosed formula, and the randomised prescription-class trial for bimatoprost in eyebrow hypotrichosis rather than any trial of this molecule; long-term data on skin pigmentation and other effects specific to dehydrolatanoprost on the brow are not published.
A verdict is DermApproved’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Evidence dots and collected reviews sit beside it and are never blended in. Rules 0.5.1 · evidence table ev-2026.09-r228 · how we decide
Ingredient lists are ordered by concentration, and the Nu-Cil Eyebrow Boosting Serum's is water, biotin, phenethyl caffeate, dehydrolatanoprost. That order is legal and probably accurate, and it is also a piece of composition: a vitamin and an antioxidant ester stand in front of the one ingredient in the tube that grows brows, which is a derivative of the glaucoma drug latanoprost and a prostaglandin analogue of the class that makes the prescription lash treatment work. Obagi's marketing calls it a proprietary lipid compound inside a biotin-led NouriPlex technology, and its safety notes, a scroll further down the page, warn that products containing prostaglandin analogs may cause iris discoloration. Both statements are on the same page. Only one of them is in the headline.
None of which changes the fact that the serum works, and works for the reason the class does. Prostaglandin analogues applied to the skin at the base of a hair prolong the growth phase of the follicle and increase the share of hairs growing at once, and in brows the evidence is unusually direct: a 2016 multicentre trial in Dermatologic Surgery randomised adults with eyebrow hypotrichosis to bimatoprost 0.03 percent once or twice daily or vehicle for seven months and found significantly more subjects improved on both bimatoprost schedules, with fullness gains from month two and darkening from month one, higher satisfaction from month two on, and, notably for a brow product, no skin or iris hyperpigmentation in the trial. Dehydrolatanoprost is a different molecule with no published trial of its own, and Obagi's twelve-week blinded study, reporting that every participant saw improved brow fill at eight weeks and nearly all saw better density and thickness, is held on file without a size; but the mechanism, the eight-week onset and the shape of the reviews all match the class.
The formula is twelve ingredients and almost identical to the brand's lash serum: water, biotin, the caffeate ester, the prostaglandin, a polymer for body, hyaluronate, an emollient ester, a glycol, alcohol, panthenol, a preservative and a pH adjuster. Biotin has no topical evidence for hair growth and is a conditioner here; hyaluronate and panthenol soften the hairs and keep the alcohol from drying the brow bone, and they are why brows feel better in the first weeks before anything grows; the caffeate is a plausible anti-irritant. It is a well-made vehicle for a single active, and the near-identical lash formula in a smaller tube costs less per millilitre, which is worth knowing for anyone tempted to buy one and use it for both.
In use the brush follows the brow's shape in one thin stroke on dry skin at night, dries in ninety seconds and vanishes. Hairs lie flatter and feel softer within two or three weeks; fill arrives from around week eight, and the reviewers who describe it describe gaps closing, tails returning and brows that need no pencil, which for over-tweezed and thinning brows is a genuine change. The hundred and ninety-odd reviews on Obagi's site sit at 4.2 stars because a minority describe the other half of the class: itch or redness along the brow bone in the first weeks, and, more often than with the lash serum, a deepening of the skin tone under and around the brow where the liquid strays. The brow is a large, visible patch of face, and darkening there shows in a way lid-line darkening under mascara does not; the 2016 bimatoprost trial saw none, which suggests dose and application discipline matter, and users who keep the stroke inside the hair and use a thin layer report far less of it.
The standing caveats are the class's. Brows return toward baseline over a few months after stopping, so the result is maintained rather than achieved; pregnancy and glaucoma drops are reasons to avoid it; reactive skin, eczema around the eyes and a tendency to post-inflammatory darkening make it a poor bet; and it should never be stacked with another prostaglandin lash or brow product.
One hundred and fifty dollars for five millilitres, about three months at nightly use, is roughly fifty dollars a month and the top of the prostaglandin brow serum market; the brand's own lash serum, near-identical in formula, costs less per millilitre, and the aesthetic brands that pioneered the category sell equivalent molecules for less again. What the money buys is Obagi's physician-channel name, a precise brush and a brand-run study; what it does not buy is a disclosed dose, a published trial or a label that says prostaglandin.
For thinning, sparse or over-tweezed brows on someone who understands what the active is, keeps the stroke inside the hair, has no pregnancy or glaucoma concerns and will keep using it, Nu-Cil fills brows the way only this class of serum does. For anyone who bought it for the biotin, or who would not have chosen a prostaglandin for a highly visible patch of face, the order of the ingredient list should have been the other way round.
The hero actives that drive this product's performance.
| Ingredient | Function | Evidence |
|---|---|---|
| Dehydrolatanoprost | Fourth on the list, behind the biotin and caffeate the brand prefers to talk about, and the only ingredient that grows brows: a dehydrated derivative of the glaucoma drug latanoprost and therefore a prostaglandin analogue, the class that has a randomised trial record for eyebrow hypotrichosis in prescription form. It lengthens the growth phase of the brow follicle, and it carries the class's side effects of skin darkening and irritation along the brow. | Not yet assessed |
| Biotin | Second on the list, above the prostaglandin, which is a placement chosen for the label rather than for the brow: topical biotin has no evidence for hair growth and conditions the brow hair at most, but it lets the NouriPlex story lead with a vitamin, and its position ahead of the active is the clearest sign of how the formula wants to be read. | Not yet assessed |
| Sodium Hyaluronate | Sixth, a humectant that keeps the alcohol-and-prostaglandin liquid from drying the thin skin of the brow and gives the brush stroke a little slip; with panthenol further down it is the comfort half of the formula, and the reason nightly use over the brow bone is tolerable for most. | Not yet assessed |
| Panthenol | Provitamin B5 near the end of the list, conditioning brow hairs so they lie better and break less in the first weeks, which is the earliest change users notice and the one that has nothing to do with the prostaglandin; a supporting player that makes the serum feel like it is doing something before it is. | Not yet assessed |
Ingredient standings describe the active at treatment-level doses and vehicles; this product's own condition grades weigh its actual formula.
Aqua/Water/Eau, Biotin, Phenethyl Caffeate, Dehydrolatanoprost, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hyaluronate, C12-15 Alkyl Benzoate, Caprylyl Glycol, Alcohol, Panthenol, Phenoxyethanol, Sodium Hydroxide
treatment
PM
Brush a thin layer along the brows from the root, following the natural shape and staying inside the line of hair, on clean, fully dry skin at night, and wait ninety seconds before eye cream or moisturiser; anything that strays onto the surrounding skin can darken it or grow hair where none is wanted. Do not combine it with another prostaglandin brow or lash product, and remove it in the morning with the usual cleanse.
Brow hairs feel softer and lie better within two or three weeks from the conditioners; new fill and density from the prostaglandin show from about eight weeks, where Obagi's study places its headline results, and continue to twelve weeks and beyond with nightly use. Brows return to baseline over a few months after stopping, and any darkening of the skin under the brow arrives in the same window as the growth.
The serum's single active is dehydrolatanoprost, a dehydrated derivative of latanoprost and therefore a prostaglandin F2-alpha analogue, the class whose lash-growing side effect in glaucoma patients gave rise to prescription lash treatment and, later, to eyebrow use. Prostaglandin analogues act on receptors in the hair follicle to extend anagen, the growth phase, and to convert a larger fraction of follicles from rest to growth, producing fuller, longer and darker hair while application continues and reverting over subsequent cycles when it stops. For brows specifically, the reference evidence is Carruthers and colleagues' 2016 multicentre, double-masked trial in Dermatologic Surgery, which randomised adult men and women with eyebrow hypotrichosis to bimatoprost 0.03 percent twice daily, once daily or vehicle twice daily for seven months; at month seven the proportion of subjects with improved overall eyebrow fullness was significantly higher in both bimatoprost groups than with vehicle, improvements in fullness and darkness appeared from months two and one respectively, subject satisfaction exceeded vehicle from month two onward, treatment-emergent adverse events were similar across groups at around 35 to 42 percent, and no skin or iris hyperpigmentation or conjunctival hyperaemia occurred. Dehydrolatanoprost is a distinct molecule marketed as a cosmetic and has no published trial; Obagi's 2022 twelve-week blinded study, reporting improved brow fill in all participants and improved density and thickness in most at eight weeks, is held on file without a published subject count. The class mechanism, the onset at four to eight weeks and the side-effect pattern in user reports are nonetheless consistent with the prescription literature.
The class's adverse effects in the lid and brow region are documented: erythema and pruritus at the application site, hyperpigmentation of periorbital skin along the treated line, hypertrichosis where the product migrates, and, for prostaglandin eye drops in light irises, permanent iris darkening; the absence of pigmentation in the seven-month bimatoprost brow trial suggests that dose and confinement to the hair-bearing skin are the main determinants, which is consistent with user reports that a thin stroke kept within the brow reduces darkening. The remaining ingredients are vehicle and conditioning: biotin has no evidence for topical hair growth and is listed above the active by concentration, phenethyl caffeate is a caffeic acid ester with in-vitro anti-inflammatory activity plausibly included to reduce irritation, sodium hyaluronate and panthenol hydrate the skin and improve hair flexibility, C12-15 alkyl benzoate provides slip, and alcohol and caprylyl glycol aid drying and preservation. The serum's efficacy therefore rests on one drug-class ingredient at an undisclosed concentration, presented within a vitamin-led complex whose other components contribute comfort rather than growth.
Brow thinning brings patients to dermatology for reasons that range from over-plucking to thyroid disease, alopecia areata and frontal fibrosing alopecia, and the first clinical step is to work out which, because a prostaglandin serum helps the first and does nothing for the last. With a benign cause established, clinicians regard prostaglandin analogues as the one topical class with trial evidence for brow fullness, and an over-the-counter version like this one as broadly interchangeable with off-label prescription bimatoprost in effect, with the prescription preferred where a disclosed dose and published safety data matter to the patient. The counselling is specific to the brow: apply only within the hair-bearing skin, use a thin layer, expect eight to twelve weeks, expect reversal on stopping, and watch for darkening of the surrounding skin, which is more visible on a brow than on a lid and more likely in patients prone to post-inflammatory pigmentation. Pregnancy, glaucoma treatment and reactive periorbital skin are the standing exclusions, and many practices ask patients to say plainly whether they know the serum is a prostaglandin before dispensing it, since the label does not.
At night, after cleansing and once the brow area is completely dry, brush a thin layer of serum along each brow from the root, following the natural shape and keeping the stroke inside the line of hair; blot any excess and do not apply to the surrounding skin, the lids or the lashes. Wait ninety seconds for it to dry before eye cream or moisturiser. Use nightly; expect softer hairs within weeks, fill from around week eight, and continued use to maintain the result. Do not combine with another prostaglandin brow or lash serum. Stop and consult a clinician if the brow bone stays red or itchy, if the skin around the brow darkens, or if any eye symptoms appear, and avoid it in pregnancy or alongside glaucoma eye drops.
One hundred and fifty dollars for five millilitres, lasting about three months at a thin nightly stroke along each brow, works out to roughly fifty dollars a month, which is the top of the prostaglandin brow serum market and above the brand's own lash serum per millilitre; there is one size and no larger option. What the money buys is an active that genuinely fills brows, a dermatology brand's name, a precise brush and a brand-run study, and for a patient of an Obagi-dispensing practice who wants the class's results without a prescription, that is a defensible if steep purchase. What it does not buy is a disclosed concentration, a published trial or a plain label, and equivalent prostaglandin brow serums from the aesthetic brands that created the category cost less, while off-label prescription bimatoprost offers a documented dose and safety record at a comparable price. Fair only for an informed buyer.
Adults with sparse, thinning or over-tweezed brows from benign causes who want the fill that only a prostaglandin serum provides, understand that the active is a prostaglandin analogue with the class's side effects, will keep the stroke inside the brow and keep using it, and have no pregnancy, glaucoma or reactive-skin concerns. It suits patients of practices that dispense Obagi and anyone who has used the lash serum successfully and wants the brow equivalent.
Pregnancy and breastfeeding rule it out, as do prostaglandin glaucoma drops, a tendency to post-inflammatory darkening, and eczema or reactive skin around the eyes. Brow loss that is sudden, patchy or accompanied by scalp or lash loss needs a diagnosis before any serum, and those who want a disclosed dose and published safety data, or a lower price for the same class of molecule, have better options.
A thin, clear, slightly viscous liquid with a faint alcohol lift, brushed along the brow in a stroke that dries within about ninety seconds to nothing visible.
None; a brief alcohol note on application that disappears as it dries.
A slim 5 mL silver metallic pen-style tube with a long screw cap and a fine brush applicator in the Nu-Cil livery; the brush suits following a brow's shape and the tube lasts about three months at nightly use, which is the price's main complaint.
The first nights are simply a brush stroke along each brow on dry skin, a faint cool tingle, and ninety seconds of waiting; a few users notice itch or pinkness along the brow bone in the first week, which is the prostaglandin and the cue to use less. Hairs feel softer and lie flatter within two to three weeks. Fill and density begin to show around week eight, and it is in the same window that some users see the skin beneath the brow take on a slightly deeper tone, which is the class's signature and reverses on stopping.
About three months at a thin nightly stroke along each brow; the brand advises continued use to maintain results.
All Year
Obagi launched Nu-Cil in mid-2025 with a lash serum and followed within weeks with this brow version, adapting the same NouriPlex prostaglandin-and-vitamin formula to the thicker, slower-cycling brow hair and backing it with a 2022 twelve-week blinded study run before the line's commercial release. The category it entered was already crowded with prostaglandin brow serums from aesthetic brands, and Obagi's contribution was its physician-channel name, a slightly higher price and a marketing vocabulary, proprietary lipid compound and biotin-led complex, that keeps the word prostaglandin off the box.
Obagi has been dispensed through dermatology offices since dermatologist Zein Obagi founded it in 1988, and Nu-Cil is its lash, brow and scalp line. The Eyebrow Boosting Serum rests on a 2022 twelve-week blinded study that Obagi holds on file without a published subject count, and on the pharmacology of prostaglandin analogues, which have a randomised trial record for brow hypotrichosis in prescription form.
The biotin listed second is what fills in the brows.
Topical biotin has no evidence for hair growth; it is placed above the active for the label's benefit. The fill comes from dehydrolatanoprost, fourth on the list, a latanoprost derivative and prostaglandin analogue of the class shown in randomised prescription trials to improve eyebrow fullness, and the vitamin and hyaluronate condition the hair while it does.
A brow serum is safer than a lash serum because it stays away from the eye.
It is further from the eye, which lowers the risk to the iris, but the skin under and around the brow is exactly where prostaglandin serums cause darkening and unwanted hair growth if the liquid strays, and it is a highly visible patch of face; keeping the stroke inside the line of hair matters more for a brow serum than for a lash one.
Yes. Dehydrolatanoprost, fourth on the ingredient list, is a derivative of the glaucoma drug latanoprost and a prostaglandin analogue; Obagi describes it as a proprietary lipid compound within its biotin-led NouriPlex complex, but it is the ingredient that produces the brow fill and the one behind the class's side effects, which the brand's own safety notes list.
Brow hairs feel softer and lie better within two to three weeks from the conditioners; fill and density from the prostaglandin appear from about eight weeks, where the brand's twelve-week study placed its results, and continue to build with nightly use. Brows return toward baseline over a few months after stopping.
It can. Prostaglandin analogues can deepen the tone of skin where they are applied, and the brow bone and the skin beneath the brow are where users of this serum report it; keeping the stroke inside the line of hair, using a thin layer and stopping if darkening appears are the safeguards, and the pigmentation generally fades after discontinuation.
Nearly. Both carry dehydrolatanoprost, biotin, panthenol and sodium hyaluronate in a light alcohol-and-water base; the brow version lists biotin and phenethyl caffeate ahead of the prostaglandin, comes in a 5 mL tube rather than 3 mL, and costs more. The lash serum should not be used on brows or vice versa without the brand's directions, since dosing differs.
Best not. Prostaglandin analogues are avoided in pregnancy as a precaution, and anyone using latanoprost, bimatoprost or similar eye drops should not add a topical prostaglandin near the eye without an ophthalmologist's approval.
About three months at a thin nightly stroke along each brow, which at one hundred and fifty dollars for five millilitres is roughly fifty dollars a month and the most frequent complaint in its reviews after skin darkening.
Recurring themes our editors read across retailer reviews of this product — summaries in our words, not quotations, and not a substitute for your own patch test.
Sparse and over-tweezed patches fill in by two months
Brows look darker and fuller without makeup
Precise brush keeps it inside the brow line
Dries fast and is invisible under products
Works where conditioning serums did nothing
Skin under the brow darkens for some
Redness or itching along the brow bone
One hundred and fifty dollars for five millilitres
Marketing does not say it is a prostaglandin
Results fade over months after stopping